Updated on August 12, 2024 at 5pm.
The FDA has granted a regenerative medicine advanced therapy (RMAT) designation for KYV-101 (Kyverna Therapeutics, Inc.) for the treatment of patients with progressive myasthenia gravis (MG), an autoimmune disorder associated with muscle weakness in tissues throughout the body. The disorder can potentially manifest into partial paralysis of eye movements, problems chewing and swallowing, respiratory complications, speech difficulties, and musculoskeletal weakness.1
About the Trial
Trial Name: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
ClinicalTrials.gov ID: NCT06193889
Sponsor: Kyverna Therapeutics
Completion Date (Estimated): May 2027
Patients who have MG develop antibodies that may lead to an immunological attack on critical signaling proteins at the junction that resides between nerve and muscle cells, therefore, hindering the nerves’ ability to properly communicate with the muscles. The symptoms of MG can be transient, and in early stages, can remit spontaneously; however, as the disease progresses, disease exacerbations can last for months and symptom-free periods are less frequent. In approximately 80% of patients,, disease symptoms reach maximum levels within 2 to 3 years, and up to 20% of patients experience respiratory crisis at least once.1
KYV-101 is an autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate. The therapy is currently being investigated in the phase 2 clinical trial KYSA-6 (NCT06193889) for the treatment of adults with refractory generalized MG. Following clearance for an investigational new drug application, KYV-101 was granted a fast track designation by the FDA in December 2023 for refractory MG.1-3
"The RMAT designation underscores the attention and interest by the FDA in the development of potentially transforming therapies targeting a severe autoimmune disease such as MG," said principal study investigator Srikanth Muppidi, MD, neuromuscular disorder specialist at Stanford Medicine in Palo Alto, CA, in a news release. "We are witnessing an era of profound changes in the approach to autoimmune conditions and ultimately, we hope this leads to a symptom-free state for patients."1
The open-label, multicenter phase 2 trial KYSA-6 (NCT06193889)—which was announced November 2023—is currently evaluating the safety, tolerability, and efficacy of KYV-101 as a treatment for patients with refractory generalized MG. Patients will receive the investigational therapy with a standard lymphodepletion conditioning regimen, cyclophosphamide (Cytoxan; Amneal Pharmaceuticals) or fludarabine (Fludara; Amneal Pharmaceuticals).3,4